Background illustration for clinical trials search

Kidney Cancer Clinical Trials

Browse 251 kidney cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

for
Advanced Clear Cell Renal Cell Carcinoma,
Location: Irvine CA, Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18+

Code: NCT07128680

Phase1, Recruiting

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

for
Advanced Renal Cell Carcinoma (aRCC),
Location: Hershey PA, Washington D.C. DC, Chapel Hill NC,
Sponsor: Brian Rini

Sex: All

Age: 18+

Code: NCT07188896

Phase2, Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

for
Renal Cell Carcinoma (RCC),
Location: Boston MA, New Haven CT, New York NY, Hackensack NJ,
Sponsor: Exelixis

Sex: All

Age: 18+

Code: NCT05176483

Phase1, Recruiting

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

for
Clear Cell Renal Cell Carcinoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07187778

Phase2, Recruiting

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

for
Renal Cell Carcinoma
Location: Boston MA, New York NY, Philadelphia PA, Nashville TN,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT07195682

Phase1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

R.E.C.K vs Exparel in Robotic Nephrectomy

for
Renal Carcinoma, Nephrectomy / Methods, Pain Management
Location: Charlotte NC
Sponsor: Wake Forest University Health Sciences

Sex: All

Age: 18+

Code: NCT07092566

Phase3, Recruiting

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

for
Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma,
Location: Pittsburgh PA
Sponsor: Diwakar Davar

Sex: All

Age: 18+

Code: NCT07223424

Phase2, Recruiting

Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis

for
Locally Advanced Renal Cell Carcinoma
Location: Richmond VA, St Louis MO, Dallas TX
Sponsor: Qian Qin

Sex: All

Age: 18+

Code: NCT06794229

Phase2, Recruiting

Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance

for
Renal Cell Carcinoma (RCC)
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute

Sex: All

Age: 18+

Code: NCT07714018

Recruiting

Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma

for
Clear Cell Renal Cell Carcinoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18 - 70

Code: NCT07564232

Phase1, Recruiting

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

for
Renal Cell Carcinoma, Urothelial Carcinoma,
Location: Boston MA, Philadelphia PA, Cleveland OH, Ann Arbor MI,
Sponsor: Deciphera Pharmaceuticals, LLC

Sex: All

Age: 18+

Code: NCT06966024

Phase1, Recruiting

Ablative Radioembolization of Renal Cell Carcinoma Trial

for
Renal Cell Carcinoma (RCC), Radioembolization
Location: London
Sponsor: Derek W. Cool

Sex: All

Age: 18+

Code: NCT06642220

Phase2, Recruiting

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

for
Ivonescimab, Clear Cell Renal Carcinoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06940518

Phase2, Recruiting

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

for
Renal Cell Carcinoma
Location: Mineola NY, New York NY, Durham NC, Pittsburgh PA,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18 - 70+

Code: NCT07049926

Phase1, Phase2, Recruiting

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

for
Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma,
Location: Boston MA, Newton MA, Commack NY, Uniondale NY,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT07227415

Phase1, Phase2, Recruiting

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

for
Renal Cell Carcinoma
Location: New Haven CT, New York NY, Fairfax VA, Cleveland OH,
Sponsor: HiberCell, Inc.

Sex: All

Age: 18+

Code: NCT06234605

Phase1, Recruiting

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

for
Solid Tumor, HNSCC, RCC, CRC
Location: Jacksonville FL, Rochester MN, Scottsdale AZ,
Sponsor: SparX Biotech(Jiangsu) Co., Ltd.

Sex: All

Age: 18+

Code: NCT06259552

Phase1, Recruiting

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

for
Advanced Clear Cell Renal Carcinoma (Ccrcc),
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT05665361

Phase1, Phase2, Recruiting

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

for
Carcinoma, Renal Cell
Location: Buffalo NY
Sponsor: State University of New York at Buffalo

Sex: All

Age: 18+

Code: NCT06222593

Phase1, Phase2, Recruiting

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

for
Metastatic Melanoma, Advanced Locoregional Melanoma,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT05155033

Phase2, Recruiting